United States Patent 8,703,820 (Adapalene 0.3% for Acne): Scope, Claims, and Patent Landscape

What is the invention claimed in US 8,703,820?

US 8,703,820 claims topical anti-acne treatment methods and regimens where the active is adapalene (0.3% by weight), specifically defined as 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthanoic acid or a salt thereof, formulated as a gel or a cream.

The claim set is structured around four enforceable pillars:

Indication/clinical target: “common acne” and related acne phenotypes (comedones, polymorphous acne, nodulocystic acne, acne conglobata, secondary acne).
Actives: adapalene at a fixed 0.3% wt concentration, not lower or higher in the independent framework.
Mode of administration: topical administration to an individual in need.
Formulation constraints: “gel or cream,” with dependent claims locking into a specific gel ingredient list and broader formulation claim templates listing multiple optional excipients.

What does claim coverage look like at a high level?

The 20 claims provided fall into three functional groups:

A. Methods (claims 1-5, 12-14)

Claim 1: topical treatment method across acne types using 0.3% adapalene gel/cream.
Claims 2-3: restrict to “common acne” and “moderate to moderately severe intensity.”
Claims 4-5: restrict formulation to a specific gel composition with an enumerated excipient set.
Claim 12: method with a structured ingredient recitation: 0.3% adapalene + one-or-more ingredients selected from a specified list + water + optional additive categories; gel or cream.
Claims 13-14: restrict to common acne and moderate to moderately severe intensity (again).

B. Regimens (claims 6-11, 15-20)

Claim 6: regimen language mirrors claim 1 (topical, 0.3% adapalene, gel/cream, acne types).
Claims 7-8: restrict to common acne and moderate to moderately severe intensity.
Claims 9-11: restrict to gel for regimen versions.
Claim 15: structured regimen ingredient template similar to claim 12 but with an expanded excipient/optional additive list.
Claims 16-17: common acne and moderate to moderately severe intensity; claims 18-20: composition is gel.

In practice, the enforceable core is: topical acne treatment using a gel or cream containing 0.3% by weight adapalene, with formulation narrowing available through dependent claims.

How specific are the claims on the formulation?

The “hard constraint”: 0.3% adapalene by weight

Every independent method/regimen claim you provided is anchored to the same active specification:

0.3% by weight adapalene (or salt)

This concentration is a “trigger” limitation. A product that uses adapalene at a different wt% does not read cleanly on these recitations.

Gel/cream requirement

Claims consistently require the composition is a gel or a cream.

Dependent claims hard-code excipient identity (claims 4-5)

Claims 4 and 5 both recite a gel comprising:

adapalene
carbomer 940
disodium edetate
methyl paraben
poloxamer 124
propylene glycol
sodium hydroxide
purified water

This is narrower than the broader templates in claims 12 and 15.

Independent-leaning composition templates (claims 12 and 15)

Claims 12 and 15 introduce “group selection” language that affects scope:

Claim 12 ingredient structure (condensed)

A gel or cream comprising:

(a) 0.3% wt adapalene or salt
(b) one or more ingredients selected from:
- carbomer 940
- carbomer 934
- propylene glycol
- perhydrosqualene
- cyclomethicone
- PEG-20 methyl glucose sesquistearate
- methyl glucose sesquistearate
(c) water
(d) optionally, one or more additives selected from:
- wetting agents
- pH regulators
- osmotic pressure modifiers
- emulsifiers
- UV-A and UV-B screening agents
- antioxidants

Claim 15 ingredient structure (condensed)

A regimen method with a composition comprising:

0.3% wt adapalene or salt
one or more ingredients selected from:
- carbomer 940
- carbomer 934
- propylene glycol
- perhydrosqualene
- cyclomethicone
- PEG-20 methyl glucose sesquistearate
- methyl glucose sesquistearate
- water
- alcohol
- polyethylene glycol
optionally additives selected from:
- wetting agents
- flavor enhancers
- preservatives
- stabilizers
- moisture regulators
- pH regulators
- osmotic pressure modifiers
- emulsifiers
- UV-A and UV-B screening agents
- antioxidants

Key scope consequence: Claims 12 and 15 are broad enough to cover many excipient substitutions as long as the selection criteria are met (the adapalene concentration and the inclusion of “water” and at least one selected excipient category are central). Dependent claims 4-5 narrow further by requiring a specific excipient set.

What acne indications are covered?

All provided method and regimen claims cover a defined acne set:

common acne
comedones
polymorphous acne
nodulocystic acne
acne conglobata
secondary acne

Claims also include explicit “common acne” and “moderate to moderately severe intensity” limitations (claims 2-3 and 7-8; mirrored in claims 13-14 and 16-17 for the structured ingredient templates).

Which claims create the strongest infringement “hooks”?

Strongest hook: independent structure with fixed 0.3% adapalene + gel/cream

The broadest independent claim format among those you provided is effectively:

topical administration of a gel or cream with 0.3% adapalene to treat acne phenotypes

A commercial topical acne product matching those elements is the most direct path to infringement.

Second hook: structured excipient templates that allow formulation latitude (claims 12 and 15)

Claims 12 and 15 contain grouped lists and optional additives. That tends to:

preserve coverage across variations in gel bases (carbomers, humectants, skin-film formers, emulsifier systems),
while keeping the active concentration fixed.

Narrowest hook: “specific gel” dependent excipient list (claims 4-5)

Claims 4-5 are highly formulation-specific and therefore less likely to be implicated unless the accused formulation uses the exact excipient package.

How broad is “salts of adapalene” in the claim language?

The phrase “adapalene or salt thereof” expands coverage to salt forms within the claim construction. Practically, this means generic design-around by switching from base adapalene to a different salt is unlikely to avoid infringement if the salt is still “adapalene” under the claim language and the concentration remains 0.3% by weight.

What is the patent landscape risk around this claim set?

Based on the claim text you supplied, the landscape risk is driven by two facts:

Adapalene topical acne products already exist in the market (adapalene is a known acne active; formulations exist as gels/creams).
This patent pins a specific concentration: 0.3% by weight, which can create a “concentration moat” against competing adapalene formulations that use other strengths or other actives.

Practical landscape segmentation (based on claim reading)

High risk: products using topical adapalene at 0.3% in a gel/cream for acne types within the claim language.
Medium risk: products using 0.3% adapalene but with excipients that fall outside the structured templates in claims 12/15. They may still be vulnerable under claim 1/6 depending on how strictly “pharmaceutically acceptable medium” is interpreted, but dependent claim coverage may not attach.
Lower risk: products using adapalene at a different concentration than 0.3% (the concentration is the main “avoidance lever” against these claims).
Lower risk: products that treat acne phenotypes not argued within “common acne” or the enumerated set, though the independent claims explicitly enumerate multiple acne categories, leaving limited wiggle room.

Claim-by-claim scope map (from your text)

Claim	Type	Primary limitations	Scope impact
1	Method	Topical treatment of listed acne types using 0.3% wt adapalene; composition is gel or cream	Broadest method format in your excerpt
2	Method	Claim 1 + “common acne”	Narrows indication
3	Method	Claim 2 + moderate to moderately severe intensity	Adds severity limitation
4	Method	Claim 1 + gel with exact excipient list (carbomer 940, disodium edetate, methyl paraben, poloxamer 124, propylene glycol, sodium hydroxide, purified water)	Narrow formulation “lock”
5	Method	Duplicates claim 4 as provided	Same narrow lock
6	Regimen	Claim 1 mirrored as “regime” language	Broad regimen version
7	Regimen	Claim 6 + “common acne”	Narrows indication
8	Regimen	Claim 7 + moderate to moderately severe intensity	Adds severity limitation
9	Regimen	Claim 6 + composition is gel	Narrows dosage form
10	Regimen	Claim 7 + composition is gel	Narrows indication + dosage form
11	Regimen	Claim 8 + composition is gel	Narrows severity + dosage form
12	Method	0.3% adapalene + selected excipient group(s) (carbomer 940/934, propylene glycol, perhydrosqualene, cyclomethicone, PEG-20 methyl glucose sesquistearate, methyl glucose sesquistearate) + water + optional additive categories; gel or cream	Broad formulation template with structured excipient “group selection”
13	Method	Claim 12 + “common acne”	Narrows indication
14	Method	Claim 13 + moderate to moderately severe intensity	Adds severity limitation
15	Regimen	Similar template to claim 12 with an expanded list including alcohol and polyethylene glycol, plus more additive categories	Broader regimen template than 12
16	Regimen	Claim 15 + “common acne”	Narrows indication
17	Regimen	Claim 16 + moderate to moderately severe intensity	Adds severity limitation
18	Regimen	Claim 15 + gel	Narrows dosage form
19	Regimen	Claim 16 + gel	Narrows indication + dosage form
20	Regimen	Claim 17 + gel	Narrows severity + dosage form

Design-around analysis (grounded in the claim wording)

Avoidance lever 1: change the adapalene wt%

If a competitor uses an adapalene concentration other than 0.3% by weight, the product likely avoids direct reading on the 0.3% limitation present across independent templates in your excerpt.

Avoidance lever 2: avoid gel/cream form

If the formulation is neither a gel nor a cream, it may not read on the “gel or cream” limitation. Many topical dosage forms in the market are gels/creams, so this lever can be difficult in practice.

Avoidance lever 3: excipient list manipulation (weaker than concentration)

If a product is at 0.3% and is a gel/cream, excipient changes are less reliable as a full design-around, because claim 1/6 use “pharmaceutically acceptable medium,” while claims 12/15 rely on “one or more ingredients selected from” specified lists. Removing all listed excipient categories and water while still achieving a stable 0.3% adapalene gel/cream is more complex than changing concentration.

Avoidance lever 4: narrow indication/severity

“Common acne” and “moderate to moderately severe intensity” appear in dependent claims (2-3, 7-8, 13-14, 16-17). But the independent templates cover a broad set of acne phenotypes; indication carve-outs based on severity alone are less protective if claims are pursued broadly.

Investment and R&D implications

Where competitors are most likely to face litigation risk

Companies planning a 0.3% adapalene gel/cream for acne will face direct risk under the independent method/regimen claim language.
Formulation-only differentiation is unlikely to be sufficient if the product stays within:
- 0.3% adapalene,
- topical gel/cream,
- acne indications enumerated in the claim.

Where a safer development path tends to sit

Different adapalene strengths than 0.3%.
Different actives or multi-active systems where adapalene is absent or not at 0.3% by weight.
Different dosage forms (not gel/cream), if commercially feasible.

Key Takeaways

US 8,703,820’s enforceable core is topical acne treatment using a gel or cream containing 0.3% by weight adapalene (or salt).
Claim 12 and 15 expand coverage through structured excipient group selections, while dependent claims 4-5 impose a specific gel excipient package.
The strongest design-around lever in your claim text is changing adapalene concentration away from 0.3%; excipient swaps alone are less reliable due to “one or more selected from” language.
Indication and severity limitations (common acne; moderate to moderately severe intensity) appear in dependent claims, but the independent scope enumerates multiple acne phenotypes, limiting reliance on marketing carve-outs.

FAQs

1) Does US 8,703,820 cover creams as well as gels?

Yes. The method and regimen claims state the composition is a gel or a cream (claims 1, 6, 12, 15; and gel-specific dependent claims 9-11, 18-20).

2) Is adapalene concentration negotiable in the claims?

No. The claims require 0.3% by weight adapalene (or a salt thereof). That concentration is a central limitation across the claim set you provided.

3) Are only “common acne” patients covered?

No. The claims enumerate multiple acne types (comedones, polymorphous acne, nodulocystic acne, acne conglobata, secondary acne). Dependent claims narrow to “common acne” and add severity.

4) What is the practical difference between claim 1 and claim 12?

Claim 1 uses a broad “pharmaceutically acceptable medium” concept for a 0.3% adapalene gel/cream. Claim 12 adds a structured list of excipients selected from defined categories plus water and optional additive categories.

5) Which claims are most formulation-specific?

Claims 4-5 are the most specific, requiring the gel to comprise an enumerated excipient list including carbomer 940, disodium edetate, methyl paraben, poloxamer 124, propylene glycol, sodium hydroxide, and purified water.

References

[1] User-provided claim text for US Patent 8,703,820 (claims 1-20).

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
France	02 03070	Mar 12, 2002

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	038924	⤷ Start Trial
Austria	417610	⤷ Start Trial
Austria	432072	⤷ Start Trial
Australia	2003216898	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Summary for Patent: 8,703,820